北京阳光诺和药物研究股份有限公司自愿披露2025年年度业绩预告的公告

Core Viewpoint - Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has voluntarily disclosed its 2025 annual performance forecast, indicating a positive growth trajectory in revenue and profit for the upcoming year [2][10]. Performance Forecast - The expected operating revenue for 2025 is projected to be between 1,192.45 million yuan and 1,371.32 million yuan, representing a year-on-year increase of 10.57% to 27.15% [2]. - The anticipated total profit for 2025 is estimated to be between 195.79 million yuan and 234.94 million yuan, reflecting a year-on-year growth of 11.25% to 33.50% [2]. - The net profit attributable to the parent company is forecasted to be between 191.05 million yuan and 229.26 million yuan, indicating a year-on-year increase of 7.69% to 29.23% [2]. - The net profit after deducting non-recurring gains and losses is expected to be between 179.70 million yuan and 215.64 million yuan, with a year-on-year growth of 8.84% to 30.61% [2]. Previous Year Performance - In the previous year, the operating revenue was 1,078.47 million yuan [4]. - The total profit was 175.99 million yuan, and the net profit attributable to the parent company was 177.41 million yuan [4]. - The net profit after deducting non-recurring gains and losses was 165.11 million yuan [4]. Reasons for Performance Changes - The company's revenue and profit are expected to grow steadily due to the deepening layout of its innovative drug pipeline, realization of value from authorized collaborations, and synergistic support from its integrated service model [6]. - The focus on innovative drug research and development, particularly in areas with global intellectual property rights, has led to a pipeline matrix that includes over 20 first-class new drugs targeting major diseases [6]. - The integration of AI technology with unique technical platforms has further enhanced the company's core competitiveness, facilitating rapid advancement of its research pipeline [6][7]. - Authorized collaborations and revenue sharing have become key drivers of profit growth, with significant income generated from the licensing of pipelines like STC007 and STC008 [7].